Advances in Therapy

, Volume 27, Issue 10, pp 731–742 | Cite as

Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: a randomized multicenter controlled trial in subjects with osteoarthritis of the knee

  • Robert M. LevyEmail author
  • Alexander Khokhlov
  • Sergey Kopenkin
  • Boris Bart
  • Tatiana Ermolova
  • Raiasa Kantemirova
  • Vadim Mazurov
  • Marjorie Bell
  • Paul Caldron
  • Lakshmi Pillai
  • Bruce P. Burnett
Original Research



Flavocoxid is a novel flavonoid-based “dual inhibitor” of the 5-lipoxygenase (5-LOX) enzyme and the cyclooxygenase (COX) enzymes. This study was designed to compare the effectiveness and safety of flavocoxid to naproxen in subjects with moderate to severe osteoarthritis (OA) of the knee.


In this randomized, multicenter, double-blind study, 220 subjects were assigned to receive either flavocoxid (500 mg twice daily) or naproxen (500 mg twice daily) for 12 weeks. The trial was structured to show noninferiority of flavocoxid to naproxen. Primary outcome measures included the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and subscales and a timed walk.


More than 90% of the subjects in both groups noted significant reduction in the signs and symptoms of knee OA. There were no statistically significant differences in efficacy between the flavocoxid and naproxen groups when the entire intent-to-treat population was analyzed. The flavocoxid group had significantly fewer upper gastrointestinal (UGI) and renal (edema) adverse events (AEs) as well as a strong trend toward fewer respiratory AEs.


Flavocoxid, a first-in-class flavonoid-based therapeutic that inhibits COX-1 and COX-2 as well as 5-LOX, was as effective as naproxen in managing the signs and symptoms of OA of the knee. Flavocoxid demonstrated better UGI, renal (edema), and respiratory safety profiles than naproxen.


5-lipoxygenase clinical trial cyclooxygenase flavocoxid, flavonoids naproxen osteoarthritis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58:26–35.CrossRefPubMedGoogle Scholar
  2. 2.
    Andersen RE, Crespo CJ, Ling SM, Bathon JM, Bartlett SJ. Prevalence of significant knee pain among older Americans: results from the Third National Health and Nutrition Examination Survey. J Am Geriatr Soc. 1999;47:1435–1438.PubMedGoogle Scholar
  3. 3.
    Dillon CF, Rasch EK, Gu Q, Hirsch R. Prevalence of knee osteoarthritis in the United States: arthritis data from the Third National Health and Nutrition Examination Survey 1991-94. J Rheumatol. 2006;33:2271–2279.PubMedGoogle Scholar
  4. 4.
    Grotle M, Hagen KB, Natvig B, Dahl FA, Kvien TK. Prevalence and burden of osteoarthritis: results from a population survey in Norway. J Rheumatol. 2008;35:677–684.PubMedGoogle Scholar
  5. 5.
    Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003;81:646–656.PubMedGoogle Scholar
  6. 6.
    Sale JE, Gignac M, Hawker G. The relationship between disease symptoms, life events, coping and treatment, and depression among older adults with osteoarthritis. J Rheumatol. 2008;35:335–342.PubMedGoogle Scholar
  7. 7.
    Salaffi F, Carotti M, Stancati A, Grassi W. Health-related quality of life in older adults with symptomatic hip and knee osteoarthritis: a comparison with matched healthy controls. Aging Clin Exp Res. 2005;17:255–263.PubMedGoogle Scholar
  8. 8.
    Jinks C, Jordan K, Croft P. Osteoarthritis as a public health problem: the impact of developing knee pain on physical function in adults living in the community: (KNEST 3). Rheumatology (Oxford). 2007;46:877–881.CrossRefGoogle Scholar
  9. 9.
    Ethgen O, Vanparijs P, Delhalle S, Rosant S, Bruyere O, Reginster JY. Social support and health-related quality of life in hip and knee osteoarthritis. Qual Life Res. 2004;13:321–330.CrossRefPubMedGoogle Scholar
  10. 10.
    Kirchner T, Aparicio B, Argentieri DC, Lau CY, Ritchie DM. Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation. Prostaglandins Leukot Essent Fatty Acids. 1997;56:417–423.CrossRefPubMedGoogle Scholar
  11. 11.
    Dannhardt G, Kiefer W. Cyclooxygenase inhibitors — current status and future prospects. Eur J Med Chem. 2001;36:109–126.CrossRefPubMedGoogle Scholar
  12. 12.
    Burnett BP, Levy R, Cole BJ. Metabolic mechanisms in the pathogenesis of osteoarthritis. A review. J Knee Surg. 2006;19:191–197.PubMedGoogle Scholar
  13. 13.
    Martel-Pelletier J, Mineau F, Fahmi H, et al. Regulation of the expression of 5-lipoxygenaseactivating protein/5-lipoxygenase and the synthesis of leukotriene B(4) in osteoarthritic chondrocytes: role of transforming growth factor beta and eicosanoids. Arthritis Rheum. 2004;50:3925–3933.CrossRefPubMedGoogle Scholar
  14. 14.
    Brune K. Safety of anti-inflammatory treatment — new ways of thinking. Rheumatology (Oxford). 2004;43(suppl. 1):i16–20.CrossRefGoogle Scholar
  15. 15.
    Hudson N, Balsitis M, Everitt S, Hawkey CJ. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut. 1993;34:742–747.CrossRefPubMedGoogle Scholar
  16. 16.
    Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation. 2005;112:759–770.CrossRefPubMedGoogle Scholar
  17. 17.
    Carmichael J, Shankel SW. Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med. 1985;78:992–1000.CrossRefPubMedGoogle Scholar
  18. 18.
    Deray G. Renal and cardiovascular effects of nonsteroidal anti-inflammatories and selective cox 2 inhibitors. Presse Med. 2004;33:483–489.CrossRefPubMedGoogle Scholar
  19. 19.
    Salahudeen AK, Reckelhoff JF, Morrow JD, Roberts LJ, 2nd. F2-isoprostanes and the kidney. Drug News Perspect. 1998;11:287–290.CrossRefPubMedGoogle Scholar
  20. 20.
    Roberts L, Morrow J. The generation and actions of isoprostanes. Biochim Biophys Acta. 1997;1345:121–135.PubMedGoogle Scholar
  21. 21.
    Basu S, Whiteman M, Mattey DL, Halliwell B. Raised levels of F(2)-isoprostanes and prostaglandin F(2alpha) in different rheumatic diseases. Ann Rheum Dis. 2001;60:627–631.CrossRefPubMedGoogle Scholar
  22. 22.
    Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520–1528.CrossRefPubMedGoogle Scholar
  23. 23.
    Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247–1255.CrossRefPubMedGoogle Scholar
  24. 24.
    Fiorucci S, Santucci L, Wallace JL, et. al. Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci USA. 2003;100:10937–10941.CrossRefPubMedGoogle Scholar
  25. 25.
    Eisen G. Lack of correspondence of risk factors and clinical GI outcomes for patients on nonsteroidal anti-inflammatory drugs (NSAIDs): analysis from the Celecoxib Long-term Arthritis Safety Study (CLASS). Gasteroenterology. 2001;120:A553.Google Scholar
  26. 26.
    Kulkarni SK, Singh VP. Licofelone: the answer to unmet needs in osteoarthritis therapy? Curr Rheumatol Rep. 2008;10:43–48.CrossRefPubMedGoogle Scholar
  27. 27.
    Cicero AF, Derosa G, Gaddi A. Combined lipoxygenase/cyclo-oxygenase inhibition in the elderly: the example of licofelone. Drugs Aging. 2005;22:393–403.CrossRefPubMedGoogle Scholar
  28. 28.
    Bertolini A, Ottani A, Sandrini M. Dual acting antiinflammatory drugs: a reappraisal. Pharmacol Res. 2001;44:437–450.CrossRefPubMedGoogle Scholar
  29. 29.
    Altavilla D, Squadrito F, Bitto A, et al. Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin stimulated macrophages. Brit J Pharmacol. 2009;157:1410–1418.CrossRefGoogle Scholar
  30. 30.
    Burnett BP, Jia Q, Zhao Y, Levy RM. A medicinal extract of Scutellaria baicalensis and Acacia catechu acts as a dual inhibitor of cyclooxygenase and 5-lipoxygenase to reduce inflammation. J Med Food. 2007;10:442–451.CrossRefPubMedGoogle Scholar
  31. 31.
    Burnett BP, Pillai L, Levy RM, editors. Flavocoxid, a natural novel flavonoid-based anti-inflammatory with a broad mechanism of action provides safe and effective inflammatory management of disease. Presented at: Society for Biomolecular Science; April 11–15, 2010; Phoenix, AZ.Google Scholar
  32. 32.
    Cao GH, Prior RL. Measurement of oxygen radical absorbance capacity in biological samples. Methods Enzymol. 1999;299:50–62.CrossRefPubMedGoogle Scholar
  33. 33.
    Morgan SL, Baggott JE, Moreland L, Desomond R, Kendrach A. The safety of flavocoxid, a medical food, in the dietary management of knee osteoarthritis. J Medicinal Foods. 2008;12:1–6.Google Scholar
  34. 34.
    Levy R, Saikovsky R, Shmidt E, Khokhlov A, Burnett BP. Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short-term randomized, double-blind pilot study. Nutrition Res. 2009;29:298–304.CrossRefGoogle Scholar
  35. 35.
    Burnett BP, Silva S, Mesches MH, Jia Q. Safety evaluation of a combination, defined extract of Scutellaria baicalensis and Acacia catechu. J Food Biochem. 2007;31:797–825.CrossRefGoogle Scholar
  36. 36.
    Baron G, Tubach F, Ravaud P, Logeart I, Dougados M. Validation of a short form of the Western Ontario and McMaster Universities Osteoarthritis Index function subscale in hip and knee osteoarthritis. Arthritis Rheum. 2007;57:633–638.CrossRefPubMedGoogle Scholar
  37. 37.
    Wolfe F. Determinants of WOMAC function, pain and stiffness scores: evidence for the role of low back pain, symptom counts, fatigue and depression in osteoarthritis, rheumatoid arthritis and fibromyalgia. Rheumatology (Oxford). 1999;38:355–361.CrossRefGoogle Scholar
  38. 38.
    Jinks C, Jordan K, Croft P. Measuring the population impact of knee pain and disability with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Pain. 2002;100:55–64.CrossRefPubMedGoogle Scholar
  39. 39.
    Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika. 1965;52:591–511.Google Scholar
  40. 40.
    Bertolini A, Ottani A, Sandrini M. Dual acting antiinflammatory drugs: a reappraisal. Pharmacol Res. 2001;44:437–450.CrossRefPubMedGoogle Scholar
  41. 41.
    Pelletier JP, Martel-Pelletier J, Raynauld JP. Most recent developments in strategies to reduce the progression of structural changes in osteoarthritis: today and tomorrow. Arthritis Res Ther. 2006;8:206.CrossRefPubMedGoogle Scholar
  42. 42.
    Naftalin RJ, Afzal I, Cunningham P, et al. Interactions of androgens, green tea catechins and the antiandrogen flutamide with the external glucose-binding site of the human erythrocyte glucose transporter GLUT1. Br J Pharmacol. 2003;140:487–499.CrossRefPubMedGoogle Scholar
  43. 43.
    Fiorani M, Accorsi A, Cantoni O. Human red blood cells as a natural flavonoid reservoir. Free Radic Res. 2003;37:1331–1338.CrossRefPubMedGoogle Scholar
  44. 44.
    Hudson N, Balsitis M, Everitt S, Hawkey CJ. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut. 1993;34:742–747.CrossRefPubMedGoogle Scholar
  45. 45.
    Badr KF. Five-lipoxygenase products in glomerular immune injury. J Am Soc Nephrol. 1992;3:907–915.PubMedGoogle Scholar
  46. 46.
    Pretorius JC. Flavonoids: a review of its commercial application potential as anti-infective agents. Curr Med Chem. 2003;2:335–353.Google Scholar
  47. 47.
    Yamada H, Takuma N, Daimon T, Hara Y. Gargling with tea catechin extracts for the prevention of influenza infection in elderly nursing home residents: a prospective clinical study. J Altern Complement Med. 2006;12:669–672.CrossRefPubMedGoogle Scholar
  48. 48.
    Manoukian AV, Carson JL. Nonsteroidal antiinflammatory drug-induced hepatic disorders. Incidence and prevention. Drug Saf. 1996;15:64–71.CrossRefPubMedGoogle Scholar
  49. 49.
    Walker AM. Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1997;40:201–208.CrossRefPubMedGoogle Scholar
  50. 50.
    Alatalo PI, Koivisto HM, Hietala JP, Puukka KS, Bloigu R, Niemela OJ. Effect of moderate alcohol consumption on liver enzymes increases with increasing body mass index. Am J Clin Nutr. 2008;88:1097–1103.PubMedGoogle Scholar

Copyright information

© Springer Healthcare 2010

Authors and Affiliations

  • Robert M. Levy
    • 1
    Email author
  • Alexander Khokhlov
    • 2
  • Sergey Kopenkin
    • 3
  • Boris Bart
    • 4
  • Tatiana Ermolova
    • 5
  • Raiasa Kantemirova
    • 6
  • Vadim Mazurov
    • 7
  • Marjorie Bell
    • 8
  • Paul Caldron
    • 9
  • Lakshmi Pillai
    • 1
  • Bruce P. Burnett
    • 1
  1. 1.Primus Pharmaceuticals, Inc.ScottsdaleUSA
  2. 2.Yaraslavl State Medical AcademyYaraslavlRussia
  3. 3.Russian State Medical UniversityMoscowRussia
  4. 4.Russian State Medical University Federal Agency of Health Care and Social DevelopmentMoscowRussia
  5. 5.St. Petersburg Medical Academy of Postgraduate StudiesSt. PetersburgRussia
  6. 6.Federal State Institute St. Petersburg Scientific and Practical Center of Medical and Social ExpertiseSt. PetersburgRussia
  7. 7.St. Petersburg Medical Academy of Postgraduate StudiesSt. PetersburgRussia
  8. 8.ClinDataServicesBloomingtonUSA
  9. 9.Arizona Arthritis and Rheumatology ResearchScottsdaleUSA

Personalised recommendations